Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-020458
Filing Date
2025-07-21
Accepted
2025-07-21 17:27:03
Documents
70
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 1423813
2 EX-31.1 ex31-1.htm EX-31.1 12304
3 EX-31.2 ex31-2.htm EX-31.2 12204
4 EX-32.1 ex32-1.htm EX-32.1 6682
5 EX-32.2 ex32-2.htm EX-32.2 6760
  Complete submission text file 0001641172-25-020458.txt   7769413

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE qlgn-20250331.xsd EX-101.SCH 58172
7 XBRL CALCULATION FILE qlgn-20250331_cal.xml EX-101.CAL 54956
8 XBRL DEFINITION FILE qlgn-20250331_def.xml EX-101.DEF 264490
9 XBRL LABEL FILE qlgn-20250331_lab.xml EX-101.LAB 437712
10 XBRL PRESENTATION FILE qlgn-20250331_pre.xml EX-101.PRE 364602
72 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1528961
Mailing Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011
Business Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011 (760) 918-9165
Qualigen Therapeutics, Inc. (Filer) CIK: 0001460702 (see all company filings)

EIN.: 263474527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37428 | Film No.: 251138137
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)